Compare Crispr Therapeutics AG (CRSP) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares Core MSCI EAFE ETF — how do they compare? Crispr Therapeutics AG trades at $50.93 (market cap $4.97B), while iShares Core MSCI EAFE ETF trades at $97.97. The key difference: iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | IEFA | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $76.78 | $98.56 |
52-Week Low | $44.34 | $81.70 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
IEFA trades at $96.15, down 1.1% on the day, with technical indicators showing a neutral to bearish short-term bias. The ETF provides exposure to developed international markets outside the US and Canada, offering diversification benefits amid S&P 500 concentration concerns. Recent news highlights IEFA's competitive 3.30% dividend yield and low 0.07% expense ratio compared to peers like VXUS and EEM.
The outlook remains balanced with potential upside from Fed rate cuts and international diversification benefits, offset by currency risks and developed market monetary policy tightening. IEFA's low-cost structure and dividend yield provide defensive characteristics, though performance depends heavily on international economic conditions and currency movements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →
